Showing results (21-30 of 31) with videos related to
Sort By:
Pageof 4
European Journal of Cancer (Oxford, England : 1990)|April 3, 2025
FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306Julian Walter Holch, Alexander J Ohnmacht, Sebastian Stintzing, et al.European Journal of Cancer (Oxford, England : 1990)|August 19, 2020
Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trialArndt Stahler, Sebastian Stintzing, Jobst C von Einem, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2025
Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in <i>RAS</i> Wild-Type Metastatic Colorectal CancerArndt Stahler, Dominik Paul Modest, Sebastian Stintzing, et al.International Journal of Cancer|December 30, 2016
Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306)Dominik P Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.European Journal of Cancer (Oxford, England : 1990)|April 13, 2025
Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancerLena Weiss, Sebastian Stintzing, Arndt Stahler, et al.International Journal of Cancer|August 25, 2021
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306)Lian Liu, Nicole Tonya Erickson, Ingrid Ricard, et al.The Lancet. Oncology|August 31, 2016
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trialSebastian Stintzing, Dominik P Modest, Lisa Rossius, et al.British Journal of Cancer|May 31, 2022
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3Laura E Fischer, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.European Journal of Cancer (Oxford, England : 1990)|August 13, 2025
Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance)Francesca Battaglin, Bert H O'Neil, Sebastian Stintzing, et al.The Lancet. Oncology|August 5, 2014
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trialVolker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, et al.Pageof 4